 JERSEY CITY, N.J., May 14, 2021 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported that it has secured a 60 million term loan facility with Hercules Capital, Inc. NYSE: HTGC and Silicon Valley Bank SVB. The capital strengthens SCYNEXIS balance sheet ahead of the anticipated commercial launch of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal product candidate for the treatment of vaginal yeast infections, which is under regulatory review by the U.S. Food and Drug Administration FDA with a PDUFA target action date of June 1, 2021. This non-dilutive financing further extends SCYNEXIS projected cash runway into 2023, based on current operating plans. 